Cost‐Utility Analysis of Biomarker‐Based vs. USG + AFP Strategies for HCC Surveillance in Chronic Hepatitis B
Alimentary Pharmacology & Therapeutics · 2026
DOI: 10.1111/apt.70386 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2026. Verfasst von Tanat Saeoui und 7 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology and Hepatology Unit, Division of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Hepatitis B, Chronic, alpha-Fetoproteins. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Faculty of Medicine, Prince of Songkla University, The Gastroenterological Association of Thailand (GAT), Guardian Angel Thrift.
Abstract (Originalsprache)
Background
The standard surveillance for hepatocellular carcinoma (HCC) involves ultrasound (USG) with alpha‐fetoprotein (AFP) every 6 months. However, limitations, such as restricted access, radiologist shortages, and uncertain cost‐effectiveness, persist.
Aims
We assessed the cost‐effectiveness of traditional and biomarker‐based HCC surveillance strategies in patients with chronic hepatitis B (CHB).
Methods
A Markov model simulated a cohort of patients with CHB to evaluate the cost‐effectiveness of various surveillance strategies: USG + AFP, GAAD, GALAD, ASAP, and no surveillance. Input parameters were sourced from literature and Thai healthcare data. The analysis adopted a societal perspective and lifetime horizon, calculating incremental cost‐effectiveness ratios (ICERs) in Thai Baht (THB) per quality‐adjusted life year (QALY) gained. Sensitivity analyses assessed robustness.
Results
ASAP every 6 months was the most cost‐effective strategy, with ICERs of 102,443 THB (~2957 USD) per QALY versus ASAP every 12 months and 76,447 THB (~2207 USD) per QALY versus no surveillance. Although GAAD and GALAD every 6 months achieved similar QALYs, they were dominated due to higher costs. Annual surveillance improved cost‐effectiveness but remained inferior to ASAP every 6 months. USG + AFP every 6 months incurred the highest lifetime cost (166,253 THB, ~4800 USD). Sensitivity analyses confirmed the robustness of ASAP every 6 months, with key drivers including biomarker costs, HCC stage utilities, and incidence rates.
Conclusions
ASAP every 6 months is the most cost‐effective HCC surveillance strategy for patients with CHB and may be particularly suitable for resource‐limited settings. Biomarker‐based surveillance should be prioritised to improve outcomes and optimise resource use.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gastroenterology and Hepatology Unit, Division of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand.
- Division of Ambulatory Medicine, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
- Division of Family and Preventive Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand.
- Division of Digital Innovation and Data Analytics, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand.
ORCID-Profile: Tanat Saeoui, Chayanis Kositamongkol, Ratthanan Chantrakul, Pimsiri Sripongpun, Naichaya Chamroonkul, Chanon Kongkamol, Pochamana Phisalprapa, Apichat Kaewdech
Förderung
- Faculty of Medicine, Prince of Songkla University
- The Gastroenterological Association of Thailand (GAT)
- Guardian Angel Thrift
Zitieren
APA
Saeoui, T., Kositamongkol, C., Chantrakul, R., Sripongpun, P., Chamroonkul, N., Kongkamol, C., Phisalprapa, P., & Kaewdech, A. (2026). Cost‐Utility Analysis of Biomarker‐Based vs. USG + AFP Strategies for HCC Surveillance in Chronic Hepatitis B. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70386
Vancouver
Saeoui T, Kositamongkol C, Chantrakul R, Sripongpun P, Chamroonkul N, Kongkamol C, et al. Cost‐Utility Analysis of Biomarker‐Based vs. USG + AFP Strategies for HCC Surveillance in Chronic Hepatitis B. Alimentary Pharmacology & Therapeutics. 2026. doi:10.1111/apt.70386
BibTeX
@article{Saeoui2026,
author = {Saeoui, Tanat and Kositamongkol, Chayanis and Chantrakul, Ratthanan and Sripongpun, Pimsiri and Chamroonkul, Naichaya and Kongkamol, Chanon and Phisalprapa, Pochamana and Kaewdech, Apichat},
title = {Cost‐Utility Analysis of Biomarker‐Based vs. USG + AFP Strategies for HCC Surveillance in Chronic Hepatitis B},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2026},
doi = {10.1111/apt.70386}
}
EUVIMED